These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 4604130)

  • 41. The human pharmacology and abuse potential of N-allylnoroxymorphone (naloxone).
    Jasinski DR; Martin WR; Haertzen CA
    J Pharmacol Exp Ther; 1967 Aug; 157(2):420-6. PubMed ID: 6039832
    [No Abstract]   [Full Text] [Related]  

  • 42. Characterization of prototypical opioid antagonists, agonist-antagonists, and agonists in the morphine-dependent rhesus monkey.
    Aceto MD
    Neuropeptides; 1984 Dec; 5(1-3):15-8. PubMed ID: 6099486
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A neuroactive steroid, dehydroepiandrosterone sulfate, prevents the development of morphine dependence and tolerance via c-fos expression linked to the extracellular signal-regulated protein kinase.
    Ren X; Noda Y; Mamiya T; Nagai T; Nabeshima T
    Behav Brain Res; 2004 Jul; 152(2):243-50. PubMed ID: 15196791
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of narcotic antagonists on fluid intake in the rat.
    Holtzman SG
    Life Sci; 1975 May; 16(9):1465-70. PubMed ID: 1134204
    [No Abstract]   [Full Text] [Related]  

  • 45. Limitations on the antagonistic actions of opioid antagonists.
    Young AM; Woods JH
    Fed Proc; 1982 May; 41(7):2333-8. PubMed ID: 7042396
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Study on novel morphine antagonists in the animal experiment (author's transl)].
    Kuhn FJ; Stockhaus K
    Arzneimittelforschung; 1976; 26(11):2009-14. PubMed ID: 1037235
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glycyl-glutamine, an endogenous beta-endorphin-derived peptide, inhibits morphine-induced conditioned place preference, tolerance, dependence, and withdrawal.
    Cavun S; Göktalay G; Millington WR
    J Pharmacol Exp Ther; 2005 Nov; 315(2):949-58. PubMed ID: 16079299
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacological approaches to the treatment of morphine-type dependence.
    Halbach H
    Int J Clin Pharmacol Biopharm; 1975 Jul; 12(1-2):6-12. PubMed ID: 1165143
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression of c-Fos in the rat central amygdala accompanies the acquisition but not expression of conditioned place aversion induced by withdrawal from acute morphine dependence.
    Jin C; Araki H; Nagata M; Shimosaka R; Shibata K; Suemaru K; Kawasaki H; Gomita Y
    Behav Brain Res; 2005 Jun; 161(1):107-12. PubMed ID: 15904717
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Morphine physical dependence in the dog.
    Martin WR; Eades CG; Thompson WO; Thompson JA; Flanary HG
    J Pharmacol Exp Ther; 1974 Jun; 189(3):759-71. PubMed ID: 4858404
    [No Abstract]   [Full Text] [Related]  

  • 51. XVI. A homeostatic and redundancy theory of tolerance to and dependence on narcotic analgesics.
    Martin WR
    Res Publ Assoc Res Nerv Ment Dis; 1968; 46():206-25. PubMed ID: 5749385
    [No Abstract]   [Full Text] [Related]  

  • 52. Physiological and behavioral approaches to the study of the quasi-morphine withdrawal syndrome.
    Valentino RJ; Smith CB; Woods JH
    Fed Proc; 1981 Apr; 40(5):1502-7. PubMed ID: 7194193
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The use of primates in screening dependence liability.
    Swain HH
    Pharmacol Ther B; 1979; 5(1-3):519-22. PubMed ID: 115019
    [No Abstract]   [Full Text] [Related]  

  • 54. [The discriminative stimulus properties of naloxone during dissociative learning in a Y maze in morphine-dependent rats].
    Bespalov AIu; Medvedev IO; Dravolina OA; Zvartau EE
    Zh Vyssh Nerv Deiat Im I P Pavlova; 1999; 49(1):96-105. PubMed ID: 10330710
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nuclear factor-kappa-B inhibitor modulates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.
    Rehni AK; Bhateja P; Singh TG; Singh N
    Behav Pharmacol; 2008 May; 19(3):265-9. PubMed ID: 18469544
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Opiate antagonists and 'blockers'.
    Murphree HB
    Am Fam Physician; 1973 Apr; 7(4):136-7. PubMed ID: 4694336
    [No Abstract]   [Full Text] [Related]  

  • 57. Behavioral and morphine-antagonist effects of the optical isomers of pentazocine and cyclazocine.
    McMillan DE; Harris LS
    J Pharmacol Exp Ther; 1972 Mar; 180(3):269-79. PubMed ID: 5012778
    [No Abstract]   [Full Text] [Related]  

  • 58. Requirements for extinction of relapse-facilitating variables and for rehabilitation in a narcotic-antagonist treatment program.
    Wikler A
    Adv Biochem Psychopharmacol; 1973; 8(0):399-414. PubMed ID: 4795072
    [No Abstract]   [Full Text] [Related]  

  • 59. Morphine withdrawal increases intrinsic excitability of oxytocin neurons in morphine-dependent rats.
    Brown CH; Stern JE; Jackson KL; Bull PM; Leng G; Russell JA
    Eur J Neurosci; 2005 Jan; 21(2):501-12. PubMed ID: 15673449
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Functional magnetic resonance neuroimaging of drug dependence: naloxone-precipitated morphine withdrawal.
    Lowe AS; Williams SC; Symms MR; Stolerman IP; Shoaib M
    Neuroimage; 2002 Oct; 17(2):902-10. PubMed ID: 12377164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.